目的 探究參麥注射液聯(lián)合噻托溴銨治療慢性阻塞性肺疾病的臨床療效。方法 選取2014年7月-2015年3月首都醫(yī)科大學(xué)宣武醫(yī)院收治的慢性阻塞性肺疾病患者68例，隨機(jī)分為對(duì)照組（31例）和治療組（37例）。對(duì)照組吸入噻托溴銨粉霧劑，18 μg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈注射參麥注射液，100 mL/次，1次/d。兩組患者連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的動(dòng)脈血?dú)庵笜?biāo)、肺功能指標(biāo)和復(fù)發(fā)的情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為74.19%、91.89%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血氧分壓（pO₂）和血氧飽和度（SpO₂）均顯著升高，而二氧化碳分壓（pCO₂）顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組第1秒用力呼吸容積（FEV1）、用力肺活量（FVC）和FEV₁/FVC均明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的升高程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。對(duì)照組和治療組的復(fù)發(fā)率分別為38.71%、10.81%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 參麥注射液聯(lián)合噻托溴銨治療慢性阻塞性肺疾病具有較好的臨床療效，可明顯改善肺功能，安全性好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Shenmai Injection combined with tiotropium bromide in treatment of chronic obstructive pulmonary disease. Methods Patients (68 cases) with chronic obstructive pulmonary disease in Xuanwu Hospital Capital Medical University from July 2014 to March 2015 were randomly divided into control group (31 cases) and treatment group (37 cases). Patients in the control group were inhalation administered with Tiotropium Bromide Powder for inhalation, 18 μg/time, once daily. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 100 mL/time, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and arterial blood gas indexes, lung function indexes, and recurrence in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.19% and 91.89%, respectively, and there was difference between two groups (P<0.05). After treatment, pO₂ and SpO₂ in two groups were significantly increased, but pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, FEV1, FVC, and FEV₁/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). The recurrence rates in the control and treatment groups were 38.71% and 10.81%, respectively, and there was difference between two groups (P<0.05). Conclusion Shenmai Injection combined with tiotropium bromide has clinical curative effect in treatment of chronic obstructive pulmonary disease, and can significantly improve lung function, with good safety,which has a certain clinical application value.